Outcomes of patients with sickle cell undergoing bone marrow transplantation
| Investigator . | Site . | Total patients . | Median follow-up (mo) . | Deaths N (%) . | cGVHD N (%) . | Rejection N (%) . |
|---|---|---|---|---|---|---|
| Walters et al10 | Multi-center | 32 | 26.5 | 2 (6.3%) | 4 (12.5%) | 4 (12.5%) |
| Abboud et al11 | South Carolina | 9 | 27.2 | 1 (11.1%) | 1 (11.1%) | 0 (0%) |
| Vermylen et al12 | Belgium | 50 | 60.0 | 2 (4.0%) | 10 (20.0%) | 5 (10%) |
| Bernaudin et al13 | France | 26 | 54.5 | 2 (7.7%) | 4 (15.4%) | 5 (19.2%) |
| Total | 117 | 47.1* | 7 (6.0%) | 19 (16.2%) | 14 (12.0%) |
| Investigator . | Site . | Total patients . | Median follow-up (mo) . | Deaths N (%) . | cGVHD N (%) . | Rejection N (%) . |
|---|---|---|---|---|---|---|
| Walters et al10 | Multi-center | 32 | 26.5 | 2 (6.3%) | 4 (12.5%) | 4 (12.5%) |
| Abboud et al11 | South Carolina | 9 | 27.2 | 1 (11.1%) | 1 (11.1%) | 0 (0%) |
| Vermylen et al12 | Belgium | 50 | 60.0 | 2 (4.0%) | 10 (20.0%) | 5 (10%) |
| Bernaudin et al13 | France | 26 | 54.5 | 2 (7.7%) | 4 (15.4%) | 5 (19.2%) |
| Total | 117 | 47.1* | 7 (6.0%) | 19 (16.2%) | 14 (12.0%) |
cGVHD = chronic graft versus host disease.
Total median follow-up time was calculated as a weighted average of the median follow-up times from the 4 studies.